Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
China
China-Japan Friendship Hospital, Beijing, Beijing Municipality The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality